stockrowBioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.
- Revenue
- +32.0%
- EPS
- −296.6%
- Free cash flow
- −52.3%
- Total debt
- +599.5%
Quarter to September 2026, against a year earlier
Follow BMRN
Alert me
BioMarin Pharmaceutical Inc. (BMRN) Net income
BioMarin Pharmaceutical Inc.'s net income for fiscal 2025 was $348.9M, down 18.3% from $426.9M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$19.1M. Over the past ten years it has ranged from −$630.2M (fiscal 2016) to $854.0M (fiscal 2020); the current reading is higher than 82% of that period. BioMarin Pharmaceutical Inc. ranks 209th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $348.9M | (18.26%) |
| FY2024 | $426.9M | 154.62% |
| FY2023 | $167.6M | 18.43% |
| FY2022 | $141.6M | — |
| FY2021 | −$64.1M | — |
| FY2020 | $854.0M | — |
| FY2019 | −$23.8M | — |
| FY2018 | −$77.2M | — |
| FY2017 | −$117.0M | — |
| FY2016 | −$630.2M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$122.8M | — |
| Jun 2026 | $44.8M | (57.58%) |
| Mar 2026 | $105.5M | — |
| Dec 2025 | −$46.6M | — |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| TGTX TG Therapeutics, Inc. compare | $441.5M |
| TECH Bio-Techne Corp compare | $181.9M |
| CAI Caris Life Sciences,�Inc. compare | $96.1M |
| BMRN BioMarin Pharmaceutical Inc. | −$19.1M |
| TWST Twist Bioscience Corporation compare | −$136.7M |
| KYMR Kymera Therapeutics, Inc. compare | −$349.4M |
| SMMT Summit Therapeutics PLC compare | −$856.1M |
| IBRX ImmunityBio, Inc. compare | −$992.4M |
| PCVX Vaxcyte, Inc. compare | −$1.1B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on BMRN
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement